Coya Therapeutics (NASDAQ:COYA) Stock Dropped to "Strong Sell" by Wall Street Zen

Key Points

• Wall Street Zen downgraded Coya Therapeutics from “sell” to “strong sell.” Other analysts remain more positive: five rate the stock Buy and one Sell, giving it a MarketBeat consensus of “Moderate Buy” and an average $15 price target.
• Coya reported a quarterly loss of $0.45 per share, worse than the $0.34 loss analysts expected. Revenue was $0.23 million, above the $0.11 million consensus estimate.
• Shares opened at $3.13, near their 52-week low of $2.72 and below both their 50-day and 200-day moving averages.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a "sell" rating to a "strong sell" rating in a note issued to investors on Saturday, Wall Street Zen reports.

A number of other research firms also recently commented on COYA. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Coya Therapeutics in a research note on Thursday, October 15th. BTIG Research reiterated a "buy" rating and set a $16.00 price objective on shares of Coya Therapeutics in a research note on Tuesday, September 15th. Roth Capital reiterated a "buy" rating and set a $12.00 price objective on shares of Coya Therapeutics in a research note on Monday, August 24th. HC Wainwright reissued a "buy" rating and issued a $18.00 target price on shares of Coya Therapeutics in a report on Thursday. Finally, Chardan Capital restated a "buy" rating and issued a $14.00 target price on shares of Coya Therapeutics in a research report on Wednesday, August 12th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Coya Therapeutics has an average rating of "Moderate Buy" and an average target price of $15.00.

Coya Therapeutics Price Performance

Shares of NASDAQ COYA opened at $3.13 on Friday. The stock has a market capitalization of $73.43 million, a PE ratio of -2.25 and a beta of 0.70. The business has a fifty day moving average price of $4.29 and a two-hundred day moving average price of $4.58. Coya Therapeutics has a fifty-two week low of $2.72 and a fifty-two week high of $6.62.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) last released its earnings results on Tuesday, November 10th. The company reported ($0.45) earnings per share for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.11). The company had revenue of $0.23 million for the quarter, compared to the consensus estimate of $0.11 million. Coya Therapeutics had a negative net margin of 643.44% and a negative return on equity of 71.48%. On average, equities analysts expect that Coya Therapeutics will post -1.34 EPS for the current year.

Hedge Funds Weigh In On Coya Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in COYA. Marshall Wace LLP grew its stake in shares of Coya Therapeutics by 29.6% during the third quarter. Marshall Wace LLP now owns 323,849 shares of the company's stock worth $1,622,000 after buying an additional 74,056 shares during the last quarter. Allworth Financial LP lifted its stake in shares of Coya Therapeutics by 1,200.0% in the 2nd quarter. Allworth Financial LP now owns 13,000 shares of the company's stock valued at $76,000 after acquiring an additional 12,000 shares during the last quarter. AXQ Capital LP bought a new position in shares of Coya Therapeutics in the 2nd quarter valued at $116,000. Long Corridor Asset Management Ltd bought a new position in shares of Coya Therapeutics in the 2nd quarter valued at $227,000. Finally, Renaissance Technologies LLC boosted its holdings in shares of Coya Therapeutics by 55.4% during the 1st quarter. Renaissance Technologies LLC now owns 103,964 shares of the company's stock valued at $410,000 after acquiring an additional 37,064 shares in the last quarter. Institutional investors own 39.75% of the company's stock.

About Coya Therapeutics

Coya Therapeutics is a clinical-stage biotechnology company developing therapies that aim to enhance the function of regulatory T cells, immune cells that help control inflammation. Its research focuses on potential treatments for neurodegenerative and other diseases associated with inflammation and immune dysfunction. The company's development programs include biologic and cell-based approaches, with candidates under investigation for conditions including amyotrophic lateral sclerosis (ALS). These therapies remain in development; Coya does not have an approved commercial product.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.